The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.
Protein kinase C, an elusive therapeutic target?
Open accessAbstract
Protein kinase C (PKC) has been a tantalizing target for drug discovery ever since it was first identified as the receptor for the tumour promoter phorbol ester in 1982. Although initial therapeutic efforts focused on cancer, additional indications — including diabetic complications, heart failure, myocardial infarction, pain and bipolar disorder — were targeted as researchers developed a better understanding of the roles of eight conventional and novel PKC isozymes in health and disease. Unfortunately, both academic and pharmaceutical efforts have yet to result in the approval of a single new drug that specifically targets PKC. Why does PKC remain an elusive drug target? This Review provides a short account of some of the efforts, challenges and opportunities in developing PKC modulators to address unmet clinical needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–226 of 226
Phase II evaluation of bryostatin-1 in metastatic melanoma
Bedikian, A. Y., Plager, C., Stewart, J. R., O'Brian, C. A., Herdman, S., Ross, M., Papadopoulos, N., Eton, O. E., Ellerhorst, J. A., & Smith, T. (2001) · Melanoma Research · doi:10.1097/00008390-200104000-00014 · Cited by 40
A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer
Marshall, J. L., Eisenberg, S. G., Johnson, M. D., Hanfelt, J., Dorr, F. A., El‐Ashry, D., Oberst, M. D., Fuxman, Y., Holmlund, J., & Malik, S. M. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.026 · Cited by 40
Advani, R. H., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J., Kwoh, T. J., Dorr, F. A., & Sikic, B. I. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2906-0 · Cited by 40
Highly specific modulators of protein kinase C localization: applications to heart failure
Qvit, N., & Mochly‐Rosen, D. (2010) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2010.07.001 · Cited by 39
Self-citationɛPKC confers acute tolerance to cerebral ischemic reperfusion injury
Bright, R., Sun, G.-H., Yenari, M. A., Steinberg, G. K., & Mochly‐Rosen, D. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.080 · Cited by 38
Self-citationPharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy
Ferreira, J. C. B., Koyanagi, T., Palaniyandi, S. S., Fajardo, G., Churchill, E. N., Budas, G. R., Disatnik, M., Bernstein, D., Brum, P. C., & Mochly‐Rosen, D. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.08.025 · Cited by 37
Self-citationSocinski, M. A., Raju, R. N., Stinchcombe, T. E., Kocs, D. M., Couch, L. S., Barrera, D., Rousey, S. R., Choksi, J. K., Jotte, R. M., Patt, D. A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd42eb · Cited by 36
Nezhat, F. R., Wadler, S., Muggia, F. M., Mandeli, J., Goldberg, G. L., Rahaman, J., Runowicz, C. D., Murgo, A. J., & Gardner, G. J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.021 · Cited by 36
Protein kinase C-β inhibition for diabetic kidney disease
Tuttle, K. R. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.041 · Cited by 34
Sheetz, M. J., Aiello, L. P., Shahri, N., Davis, M. D., Kles, K. A., & Danis, R. P. (2011) · Retina · doi:10.1097/iae.0b013e3181fe545f · Cited by 33
Reducing readmissions for congestive heart failure.
Hoyt, R. E., & BOWLING, L. S. (2001) · PubMed · Cited by 31
Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer
Brockstein, B., Samuels, B. L., Humerickhouse, R. A., Arrieta, R. L., Fishkin, P. A. S., Wade, J., Sosman, J. A., & Vokes, E. E. (2001) · Investigational New Drugs · doi:10.1023/a:1010628903248 · Cited by 31
Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas, N. B., Smith, M. R., Lewis, N. L., Littman, L., Yeslow, G., Joshi, I. D., Murgo, A. J., Bradley, J., Gordon, R., Wang, H., et al. (2003) · PubMed · Cited by 30
Lee, S. K., Chung, J. I., Park, M. S., Joo, H. K., Lee, E. J., Cho, E., Park, J. B., Ryoo, S., Irani, K., & Jeon, B. H. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr095 · Cited by 30
Persaud, S. D., Hoang, V., Huang, J., & Basu, A. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.1.149 · Cited by 28
Protein kinase C isozymes as potential therapeutic targets in immune disorders
Lee, M. R., Duan, W., & Tan, S. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.5.535 · Cited by 28
Deuse, T., Koyanagi, T., Erben, R. G., Hua, X., Velden, J., Ikeno, F., Reichenspurner, H. C., Robbins, R. C., Mochly‐Rosen, D., & Schrepfer, S. (2010) · Circulation · doi:10.1161/circulationaha.109.927640 · Cited by 27
Self-citationLahn, M. M. F., Sundell, K. L., & MOORE, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.029 · Cited by 25
Glimelius, B. L. G., Lahn, M. M. F., Gawande, S. R., Cleverly, A., Darstein, C., Musib, L. C., Liu, Y., Spindler, K.-L. G., Frödin, J., Berglund, Å., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp521 · Cited by 25
Jin, Z., Duan, W., Chen, M., Yu, S., Zhang, H., Feng, G., Xiong, L., & Yi, D. (2011) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.12.052 · Cited by 25
Pfister, D. G., McCaffrey, J., Zahalsky, A. J., Schwartz, G. K., Lis, E., Gerald, W. L., Huvos, A. G., Shah, J. P., Kraus, D. H., Shaha, A. R., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1014449309165 · Cited by 23
Hypertensive encephalopathy and the blood-brain barrier: is δPKC a gatekeeper?
Chou, W.-H., & Messing, R. O. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34516 · Cited by 23
Rini, B. I., WEINBERG, V. K., Shaw, V., Scott, J. H., Bok, R., Park, J. W., & Small, E. J. (2004) · Cancer · doi:10.1002/cncr.20313 · Cited by 19
PKCη is a novel prognostic marker in non-small cell lung cancer.
Krasnitsky, E., Baumfeld, Y., Freedman, J., Sion‐Vardy, N., Ariad, S., Novack, V., & Livneh, E. (2012) · PubMed · Cited by 19
Sarma, N. J., Tiriveedhi, V., Angaswamy, N., & Mohanakumar, T. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.06.014 · Cited by 14
Simonis, G., BRAUN, M. U., Kirrstetter, M., Schön, S., & Strasser, R. H. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200305000-00016 · Cited by 14
Cited by
Ros and ros-mediated cellular signaling
Zhang, J., Wang, X., Vikash, V., Ye, Q., Wu, D., Liu, Y., & Dong, W. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4350965 · Cited by 1,980
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis
Zhang, H.-L., Hu, B.-X., Li, Z.-L., Du, T., Shan, J.-L., Ye, Z.-P., Peng, X.-D., Li, X., Huang, Y., Zhu, X.-Y., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00818-3 · Cited by 582
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Metadata
- Authors
- Mochly-Rosen, D., Das, K., & Grimes, K. V.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-11-30
- Volume
- 11
- Issue
- 12
- Pages
- 937-957
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2004585452
- Cited by
- 563
- References
- 226
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.